816 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
BMY Bristol-Myers Squibb Company $61.3 $100.03B N/A
Article Searches
Roche (RHHBY) Up 6.3% YTD on Strong Demand for New Drugs http://www.zacks.com/stock/news/422851/roche-rhhby-up-63-ytd-on-strong-demand-for-new-drugs?cid=CS-ZC-FT-422851 May 31, 2019 - Roche's (RHHBY) performance has been strong in the year so far, driven by solid growth of Ocrevus, Perjeta, Tecentriq and Hemlibra.
Novartis (NVS) Reports Positive Phase III Data on Asthma Drug http://www.zacks.com/stock/news/422639/novartis-nvs-reports-positive-phase-iii-data-on-asthma-drug?cid=CS-ZC-FT-422639 May 31, 2019 - Novartis' (NVS) investigational, once-daily, fixed dose combination asthma candidate, containing indacaterol acetate and mometasone furoate, meets goals.
BMY or NVO: Which Is the Better Value Stock Right Now? http://www.zacks.com/stock/news/421291/bmy-or-nvo-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-421291 May 29, 2019 - BMY vs. NVO: Which Stock Is the Better Value Option?
Celgene's Revlimid-Rituximab Combo Gets FDA Nod for Lymphoma http://www.zacks.com/stock/news/421410/celgenes-revlimid-rituximab-combo-gets-fda-nod-for-lymphoma?cid=CS-ZC-FT-421410 May 29, 2019 - Celgene's (CELG) Revlimid in combination with a rituximab product gets FDA approval for the treatment of adult patients with previously treated follicular lymphoma or marginal zone lymphoma.
This Just In: Goldman Sachs Picks 4 Big Pharma Stocks to Buy https://www.fool.com/investing/2019/05/28/this-just-in-goldman-sachs-picks-4-big-pharma-stoc.aspx?source=iedfolrf0000001 May 28, 2019 - And the analyst really likes one in particular.
Novartis Gets FDA Nod for Breast Cancer Drug & Gene Therapy http://www.zacks.com/stock/news/420120/novartis-gets-fda-nod-for-breast-cancer-drug-gene-therapy?cid=CS-ZC-FT-420120 May 27, 2019 - Novartis (NVS) obtains FDA approvals for a breast cancer drug and a gene therapy for pediatric patients.
Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now http://www.zacks.com/stock/news/420048/why-bristol-myers-squibb-bmy-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-420048 May 27, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Roche Gets FDA Nod for Expansion of Cobas 6800/8800 Systems http://www.zacks.com/stock/news/419984/roche-gets-fda-nod-for-expansion-of-cobas-6800-8800-systems?cid=CS-ZC-FT-419984 May 27, 2019 - Roche (RHHBY) gets FDA clearance for the expansion of its leading testing menu.
Novartis Reports Data on Asthma Drug, Update from Annual Meet http://www.zacks.com/stock/news/418681/novartis-reports-data-on-asthma-drug-update-from-annual-meet?cid=CS-ZC-FT-418681 May 23, 2019 - Novartis (NVS) reports encouraging data on combination asthma drug. The company also highlights its growth plans at its annual meet.
Mallinckrodt (MNK) Down After Filing Suit Against HHS and CMS http://www.zacks.com/stock/news/418120/mallinckrodt-mnk-down-after-filing-suit-against-hhs-and-cms?cid=CS-ZC-FT-418120 May 22, 2019 - Mallinckrodt (MNK) declines after filing suit against HHS and CMS for the protection of Medicaid patient access to Acthar.

Pages: 123456789...82

<<<Page 4>